Two options, one starting point
NIDDK says weight-management medicines do not replace physical activity or healthy eating and work best within a lifestyle programme [1]. Its surgery pages make the same point from the other side: surgery makes it easier to eat less and move more, but the long-term result depends on lifelong habits and the advice of the care team [2].
Neither page presents the two as rivals. If a medicine does not help enough, the medicines page says a clinician may refer you to a bariatric surgeon [1]; the surgery pages describe candidates as people for whom eating plans, exercise or medicines have not been enough [2].
Who each is meant for
- Medicines: a clinician may prescribe them for adults with a BMI of 30 or more, or 27 or more with a weight-related problem such as high blood pressure or type 2 diabetes. NIDDK adds that they are not for everyone with a high BMI and are not to be used in pregnancy or while planning one [1].
- Surgery: NIDDK lists adults with a BMI of 40 or more, 35 or more with a serious obesity-related problem such as type 2 diabetes, heart disease or sleep apnea, or 30 or more with type 2 diabetes that medical treatment and lifestyle changes have not brought under control [3].
- Teenagers: NIDDK lists four medicines approved from age 12: orlistat, liraglutide (Saxenda®), phentermine-topiramate and semaglutide (Wegovy®) [1]. For surgery, it cites guidelines in which teens are evaluated by a multidisciplinary team with paediatric expertise [3].
How each works
The medicines page lists the drugs the FDA has approved for long-term weight management, including liraglutide (Saxenda®), semaglutide (Wegovy®) and tirzepatide (Zepbound®), alongside older options [1]. It was last reviewed in June 2024, so it does not include later approvals such as orforglipron (Foundayo™) tablets, whose label covers reducing excess weight and maintaining the reduction long term, with diet and activity [8].
Surgery changes the digestive system itself. A smaller stomach brings fullness sooner, changes to the small intestine reduce the calories absorbed, and gut hormones and bacteria may shift in ways that reduce appetite [2].
The main US operations are the gastric sleeve, which removes about 80% of the stomach and cannot be reversed, gastric bypass, which is difficult to reverse, and the adjustable band, now performed less often because of more complications, mainly removal of the band [4].
What each involves, side by side
The table deliberately leaves out weight-loss percentages. NIDDK’s figures for medicines and for surgery come from different studies of different people, so putting them in one row would suggest a comparison those numbers cannot support. The section after it uses studies that measured both.
| Weight-management medicines | Bariatric surgery | |
|---|---|---|
| Who it is for | Adults with BMI 30+, or 27+ with a weight-related problem [1] | Adults with BMI 40+, 35+ with a serious related problem, or 30+ with hard-to-control type 2 diabetes [3] |
| How it works | Medicine taken alongside diet and activity; some GLP-1 medicines slow stomach emptying [1][6] | Smaller stomach, changes to the small intestine, shifts in gut hormones [2] |
| Reversible? | Can be stopped; NIDDK expects some weight to return afterwards [1] | Sleeve cannot be reversed; bypass is difficult to reverse; band can be removed [4] |
| How long | As long as it works without serious side effects, possibly long term [1] | One operation, then lifelong follow-up, vitamins and minerals [3][4] |
| Risks the sources name first | Mostly mild stomach effects; rare serious ones such as pancreatitis and gallbladder disease [1][6] | Bleeding, infection, leaks, blood clots; later nutrient shortages, gallstones, strictures, hernias [5] |
| Before it starts | Review of your health, other conditions and treatments [1] | Visits with an internist, a dietitian, a psychiatrist or psychologist and the surgeon [4] |
What studies that measured both found
A few research groups have followed adults who chose a GLP-1 medicine and adults who chose surgery within the same study. The largest, from two New York health systems, used records of 44,025 adults with a BMI of 35 or more treated between 2018 and 2024 and adjusted statistically for differences between the groups [9]. Its intention-to-treat results are in the table below; among people with a full year of continuous semaglutide orders, loss reached 8.8% at year 3 [9].
A prospective study in China let 71 adults choose between a gastric sleeve and weekly semaglutide. At 12 months, weight loss averaged 28.6% after surgery and 11.3% with semaglutide; the medicine was planned for 24 weeks, and of the 25 people who stopped after 6 months, 32% were back at or above their starting weight by 12 months [10]. A US retrospective study of 812 adults reported 27.8% after surgery and 11.1% with a GLP-1 medicine at one year; the medicine group was older and had higher heart risk at the start [11].
| Group | Year 1 | Year 2 | Year 3 |
|---|---|---|---|
| Semaglutide (25,804 people) | 5.4% | 6.5% | 7.4% |
| Tirzepatide (7,308 people) | 9.1% | 10.8% | not reported |
| Gastric sleeve (8,728 people) | 24.4% | 22.4% | 22.0% |
| Gastric bypass (2,185 people) | 29.8% | 28.1% | 28.4% |
How far those results go
- People chose their treatment. Statistical adjustment narrows the gap between groups but cannot remove every difference in health, motivation or access [9][10][11].
- Medicine use was not always continuous. The semaglutide group in the China study was planned for 24 weeks, and the New York study shows higher loss when only people with a year of continuous orders were counted [9][10].
- Each study comes from one or two centres, which limits how well it describes other places and populations [9][10][11].
- No randomized head-to-head trial was available to the 2026 network meta-analysis: it pooled 30 randomized trials, and every surgery-versus-medicine comparison in it was indirect [12].
- Weight is one outcome. NIDDK also describes surgery improving conditions such as type 2 diabetes, while a medicine can be stopped; how those trade-offs apply to you is a clinical question [1][2].
Risks NIDDK and the labels list
- Medicines: side effects depend on the drug. NIDDK says most are mild and often ease, but serious ones can rarely occur and in some cases may outweigh the benefits [1].
- Surgery, early: bleeding, infection, leaks where the stomach or intestine was joined, diarrhoea and blood clots. About one-third of patients need a further procedure, operation or hospital stay within 5 years, more often after bypass than sleeve, and in rare cases complications are fatal [5].
- Surgery, later: nutrient shortages that can lead to anaemia or osteoporosis, gallstones after rapid weight loss, narrowing at the join, hernias, and possible changes in how alcohol is absorbed and broken down [5].
- Gallbladder, on the medicine side: in the Wegovy® adult weight trials, gallstones were reported in 1.6% on the injection against 0.7% on placebo, and the label says the excess remained after accounting for how much weight was lost [6].
- Any operation while on a GLP-1: the Wegovy® and Zepbound® labels describe rare reports of food left in the stomach and inhaled under anaesthesia despite fasting, and ask patients to tell their care team about the medicine before any planned procedure [6][7].
When both are part of the picture
Surgery and medicine are sometimes used one after the other. BARI-STEP, a double-blind randomized trial in London, enrolled 70 adults at least a year after a bypass or sleeve who had lost less than 20% of their weight. Over 68 weeks, alongside a lifestyle programme, weight changed by an average of −18.0% with semaglutide 2.4 mg and +0.4% with placebo, with no new safety concerns reported [13].
The labels add cautions for this group. The Wegovy® label names a history of bariatric surgery as a risk factor for low blood sugar and reports serious episodes in 2 of 87 such people on the injection and none of 97 on placebo [6]. The EU product information for Rybelsus® notes that there is no treatment experience with semaglutide in people who have had bariatric surgery [14]. NIDDK lists teens and young adults with too little loss after surgery among the groups now being studied with medicines [1].
Commitment and duration
NIDDK says how long a medicine is taken depends on whether it works and whether serious side effects appear, and a clinician may continue it indefinitely. If weight loss is under 5% after 12 weeks on the full dose, a clinician will probably advise stopping; some weight is likely to return after it is stopped [1].
Before surgery, NIDDK describes the pre-operative visits listed in the table. Afterwards, eating moves from liquids to soft foods and then to solids over several weeks, prescribed vitamins and minerals become routine, and NIDDK gives a US cost of about $15,000 to $25,000 or more, adding that Medicare and some Medicaid programmes may cover the main operations when certain criteria are met [2][4].
Questions to bring to the appointment
NIDDK suggests questions for anyone weighing surgery: have other methods worked, do you understand the operation and its risks, how will eating and activity need to change, and can you keep up lifelong habits, follow-up and supplements [3]. For medicines it covers the likely benefit, side effects, your other conditions and how long treatment may last [1].
If you already take a GLP-1 medicine and surgery is being discussed, the list grows: when to tell the surgical team about it, what happens to the medicine around the operation, and whether it could be used again later. Those answers come from your clinicians, not from a label table.
Saxenda®, Wegovy® and Rybelsus® are registered trademarks of Novo Nordisk A/S. Zepbound® is a registered trademark and Foundayo™ is a trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Novo Nordisk or Eli Lilly and Company.
When to get help
| Sign | Who to contact | How fast | Source |
|---|---|---|---|
| Severe stomach pain that will not go away, with or without vomiting, while on a GLP-1 medicine | Your prescriber, right away | Today | Wegovy® Medication Guide; label section 5.2 [6] |
| Pain in the upper stomach, yellow skin or eyes, fever or clay-coloured stools | Your prescriber | Today | Wegovy® Medication Guide; label section 5.3 [6] |
| After bariatric surgery: trouble breathing, a swelling leg, fever above 100°F (37.7°C) for more than 4 hours, or being unable to eat or drink | Your surgeon | Today | MedlinePlus, gastric bypass discharge [15] |
| Dizziness, sweating, blurred vision or other signs of low blood sugar on a GLP-1 after a bariatric operation | Your prescriber | Today | Wegovy® label, sections 5.4 and 6.1 [6] |
| A planned operation or procedure with anaesthesia or deep sedation while you take a GLP-1 | The surgical and anaesthesia team, before the day | At your next appointment | Wegovy® label 5.10; Zepbound® label 5.9 [6][7] |
